• Program Director, William T Dahms Clinical Research Unit, UH Cleveland Medical Center
  • Director, Clinical Hypertension Program, UH Cleveland Medical Center
  • Professor Emeritus, Medicine, CWRU School of Medicine

(216)844-8060

  • Gender: Male
  • Online Personal Health Record Available

Bio

JACKSON T. WRIGHT, JR., MD, PHD, FACP, FASH, FAHA is Professor of Medicine and Program Director of the William T Dahms MD Clinical Research Unit at University Hospitals Cleveland Medical Center. He is also Director of the Clinical Hypertension Program in the Division of Nephrology and Hypertension. He received both his MD and Ph.D. (Pharmacology) from the University of Pittsburgh and completed his Internal Medicine residency at the University of Michigan. He is board certified in Internal Medicine and received subspecialty board certification in Clinical Pharmacology. An experienced clinical investigator, Dr. Wright’s primary research interest is in the clinical pharmacology of antihypertensive and cholesterol lowering agents, especially in minority populations. He has published extensively in this area (over 300 articles, book chapters and abstracts) and served on many national and international advisory panels.

Dr. Wright has had a major or leadership role in nearly all of the major clinical outcome trials conducted in black populations over the past two decades. His leadership and participation in National Institutes of Health-funded clinical trials with large minority representation has resulted in significant advancement of the knowledge base for treatment of hypertension and chronic kidney disease. He served as Vice Chair of the Steering Committee for the NIH-sponsored African American Study of Kidney Disease in Hypertensives Trial (AASK) and first authored its primary results paper. In addition, he is Co-I (initially PI) of one of seven clinical center networks to participate in the National Institute of Diabetes and Digestive and Kidney Diseases-sponsored Chronic Renal Insufficiency Cohort (CRIC) Study.

Dr. Wright also served as Chair of the Executive Committee and Vice Chair of the Steering Committee for the largest study of hypertension treatment ever completed, the Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial (ALLHAT), where he was the lead author on the primary results paper and the papers presenting the results by race. The study defined optimal hypertensive therapeutic regimens to reduce cardiovascular events, pointing out differences in magnitude of response by ethnicity. It also demonstrated the impact of quality clinical trial data derived from diverse cohorts in optimizing treatment in these same populations. He is currently PI of one of the five clinical center networks in the National Heart, Lung, and Blood Institute-sponsored Systolic Blood Pressure Intervention Trial (SPRINT).

He was selected for service on the three latest U.S. national hypertension guideline panels. He co-chaired the treatment section for the previous Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), served on the panel that generated the 2014 U.S. hypertension guideline report, and currently serves on the hypertension guideline panel convened by the American Heart Association and American College of Cardiology.

Board Certifications

American Board of Internal Medicine - Internal Medicine

Education & Training

Undergraduate

1967, Ohio Wesleyan University

Medical / Professional School(s)

1976, University of Pittsburgh School of Medicine

Internship

1978, Internal Medicine - University of Michigan Hospitals and Health Centers

Residency

1980, Internal Medicine - University of Michigan Hospitals and Health Centers

Expertise

Evaluaton and Management of Resistant Hypertension

Office Locations

UH Cleveland Medical Center
(216)844-8060
Department of Medicine-Hypertension
11100 Euclid Ave
Cleveland, OH 44106
Get Directions

Selected Publications

Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes.
Barzilay JI, Davis BR, Ghosh A, Pressel SL, Rahman M, Einhorn PT, Cushman WC, Whelton PK, Wright JT Jr, ALLHAT Collaborative Research Group.

Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).
Townsend RR, Anderson AH, Chirinos JA, Feldman HI, Grunwald JE, Nessel L, Roy J, Weir MR, Wright JT Jr, Bansal N, Hsu CY, CRIC Study Investigators.

Serum Bicarbonate Concentration and Cognitive Function in Hypertensive Adults.
Dobre M, Gaussoin SA, Bates JT, Chonchol MB, Cohen DL, Hostetter TH, Raphael KL, Taylor AA, Lerner AJ, Wright JT Jr, Rahman M, SPRINT Research Group.

Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial).
Johnson KC, Whelton PK, Cushman WC, Cutler JA, Evans GW, Snyder JK, Ambrosius WT, Beddhu S, Cheung AK, Fine LJ, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Oparil S, Wright JT Jr, SPRINT Research Group.

Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease.
Rahman M, Hsu JY, Desai N, Hsu CY, Anderson AH, Appel LJ, Chen J, Cohen DL, Drawz PE, He J, Qiang P, Ricardo AC, Steigerwalt S, Weir MR, Wright JT Jr, Zhang X, Townsend RR, CRIC Study Investigators.

The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications.
Barzilay JI, Davis BR, Pressel SL, Ghosh A, Rahman M, Einhorn PT, Cushman WC, Whelton PK, Wright JT Jr

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr

Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.
Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, Whelton PK

Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline.
Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, Whelton PK

View All Publications

Patient Satisfaction Reviews

About Our Survey

At University Hospitals, we believe in providing patients with all the information they need to make educated decisions about their health care and to choose the right doctor to meet their needs. That is why we partner with the independent patient satisfaction company Press Ganey to survey patients about their experiences at UH facilities and with UH physicians. We hold ourselves to the highest standards of care and are dedicated to creating a positive patient experience for every individual who sees a UH doctor.

Learn More

Patient Comments

There are no comments for this practitioner.

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Jackson Wright, MD, PhD disclosed the following Outside Relationships with Industry:


Medtronic, Inc. - Consulting

Takeda Pharmaceuticals - Consulting

There is no publicly available rating for this medical professional because he or she either does not see patients or has not yet received the minimum number of Patient Satisfaction Reviews. To be eligible for display, we require a minimum of 30 surveys. This ensures that the rating is statistically reliable and a true reflection of patient satisfaction.

UH Quality Care Network, is a collaboration among independent and UH employed providers. The focus is on improving the quality and efficiency of care, as well as reducing the cost of care.